

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Enteral liquid peptide formula

INITIATION

Prerequisites (tick boxes where appropriate)

Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable
and

- Severe malabsorption
- or**
- Short bowel syndrome
- or**
- Intractable diarrhoea
- or**
- Biliary atresia
- or**
- Cholestatic liver diseases causing malabsorption
- or**
- Cystic fibrosis
- or**
- Proven fat malabsorption
- or**
- Severe intestinal motility disorders causing significant malabsorption
- or**
- Intestinal failure

- The patient is currently receiving funded amino acid formula
and
 The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula

- and**
- A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable
 - or**
 - For step down from intravenous nutrition

Note: A reasonable trial is defined as a 2-4 week trial.

CONTINUATION

Prerequisites (tick boxes where appropriate)

- An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken
and
 The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: Date: